Evidence map›Paper›PMID 38309732›Full record

ArticleSaudi medical journal2024

Epidemiology of

Naoufel M Kaabia, Hanadi Al Basha, Dalal A Bukhari, Nabiha Bouafia, Aeshah N Al Qahtani, Ahmad M Alshahrani, Ismail M Aboushanab, Abdulrahman N Al Odayani

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. The Global Burden ofInfectious disease reports · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Naoufel M KaabiaFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.ORCID https://orcid.org/0000-0002-1338-0546
Hanadi Al BashaFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Dalal A BukhariFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Nabiha BouafiaFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Aeshah N Al QahtaniFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Ahmad M AlshahraniFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Ismail M AboushanabFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Abdulrahman N Al OdayaniFrom the Infection Control and Prevention Centre of Excellence (Kaabia, Al Basha, Bukhari, Bouafia, Al Qahtani, Aboushanab, Al Odayani), Prince Sultan Military Medical City, and from the Department of specialty? (Alshahrani), Al Maarefa University, Riyadh, Kingdom of Saudi Arabia.
Sulaiman Al Rajhi Colleges · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine the incidence of

methodsA prospective hospital-based surveillance for CDI, according to the Centers for Disease Control and Prevention criteria, was carried out from July 2019 to March 2022 for all inpatients aged more than one year in Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

resultsA total of 139 cases of CDI were identified during the survey among 130 patients admitted in the hospital. Most cases were incident (n=130; 93.5%), and almost three-quarters (n=102; 73.4%) were hospital-onset (HO) CDI, with an incidence rate of 1.62 per 10,000 patient days (PD). The highest rates were noted in intensive care units with an incidence rate of 3 per 10,000 PD and wards for immunocompromised patients with an incidence rate of 2.72 per 10,000 PD. The most prevalent risk factor for CDI was acid-reducing drugs (72.6%). Vancomycin (48%) and ciprofloxacin (25%) were the most frequently prescribed antibiotics for patients with CDI.

conclusionIn our hospital, HO-CDI incidence rate is lower than that in high-income countries. National multicenter surveillance is needed to evaluate the actual burden of CDI in Saudi Arabia.

Indexed as

Clostridioides difficileClostridium InfectionsCross InfectionHumansProspective StudiesSaudi ArabiaTertiary Health CareClostridioides difficileincidenceoutcomerisk factorSaudi Arabia

Identifiers

PMID38309732
PMCPMC11115418
OpenAlexW4391511371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.